Business Context and Reporting Period
Company: Entrada Therapeutics, Inc. (TRDA)
Filing Type: Form 8-K (Current Report)
Date of Report: May 18, 2026
Reporting Period: Single event date (May 18, 2026)
Business Context: The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in Boston, MA. The filing serves as a Regulation FD disclosure regarding an update to the company's corporate presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation update and does not contain audited financial statements or quarterly results.
Material Changes
Corporate Presentation Update: On May 18, 2026, Entrada Therapeutics updated its corporate presentation for use in meetings with investors and analysts. This updated presentation is furnished as Exhibit 99.1.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates the updated corporate presentation by reference but explicitly states that the information in Item 7.01 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act. Consequently, it is not subject to the liability of such section nor incorporated by reference in other filings unless expressly stated.
Risks and Contingencies: No specific risks or contingencies are detailed within the text of this 8-K filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation dated May 2026) for specific updates to the company's pipeline, financial outlook, or operational strategy.
- Verify the status of the company as an "emerging growth company" and any implications for financial reporting standards.
- Confirm that the information in the corporate presentation is not legally "filed" under Section 18 of the Exchange Act, limiting liability for forward-looking statements contained therein.
- Check subsequent filings (e.g., 10-Q or 10-K) for the actual financial metrics referenced in the updated presentation.